Importantly, the observed plasma miRNAs, such as miR-208b-3p and miR-587-5p, inhibit CDH2 gene expression and may act as both biomarkers and new directions for implementing miRNAs in the treatment of fully symptomatic MM, as well as preventive measures to prevent its progression from MGUS. Here, CDH2 is linked to Miyoshi myopathy.